High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2022-03-01
|
| Col·lecció: | Molecular Therapy: Methods & Clinical Development |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2329050122000043 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|